Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening

被引:15
作者
Gu, Shengqing [1 ,2 ,12 ]
Lheureux, Stephanie [1 ,3 ]
Sayad, Azin [1 ]
Cybulska, Paulina [1 ,4 ]
Hogen, Liat [1 ,4 ]
Vyarvelska, Iryna [1 ,4 ,13 ]
Tu, Dongsheng [5 ]
Parulekar, Wendy R. [5 ]
Nankivell, Matthew [6 ]
Kehoe, Sean [7 ]
Chi, Dennis S. [8 ,9 ]
Levine, Douglas A. [10 ]
Bernardini, Marcus Q. [1 ,4 ]
Rosen, Barry [1 ,4 ,14 ]
Oza, Amit [1 ,3 ]
Brown, Myles [11 ,12 ]
Neel, Benjamin G. [1 ,2 ,10 ]
机构
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada
[3] Univ Toronto, Div Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada
[4] Univ Toronto, Div Gynecol Oncol, Toronto, ON M5G 2M9, Canada
[5] Queens Univ, Canadian Canc Trials Grp, Kingston, ON K7L 3N6, Canada
[6] UCL, Med Res Council, Clin Trials Unit, London WC1V 6LJ, England
[7] Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England
[8] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10065 USA
[9] Weill Cornell Med Coll, Dept Obstet & Gynecol, New York, NY 10021 USA
[10] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, 550 1St Ave, New York, NY 10016 USA
[11] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA
[12] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[13] McMaster Univ, Dept Obstet & Gynecol, Hamilton, ON L8S 4L8, Canada
[14] Beaumont Hosp, Dept Gynecol Oncol, Royal Oak, MI 48073 USA
基金
英国医学研究理事会;
关键词
ovarian cancer; computational; neoadjuvant chemotherapy; primary debunking surgery; PRIMARY DEBULKING SURGERY; NEOADJUVANT CHEMOTHERAPY; CISPLATIN RESISTANCE; SURGICAL CYTOREDUCTION; PERITONEAL CARCINOMA; DRUG-RESISTANCE; TIME-INTERVAL; CELL-LINES; EXPRESSION; EVOLUTION;
D O I
10.1073/pnas.2026663118
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
High-grade serous tubo-ovarian carcinoma (HGSC) is a major cause of cancer-related death. Treatment is not uniform, with some patients undergoing primary debulking surgery followed by chemotherapy (PDS) and others being treated directly with chemotherapy and only having surgery after three to four cycles (NACT). Which strategy is optimal remains controversial. We developed a mathematical frame-work that simulates hierarchical or stochastic models of tumor initi-ation and reproduces the clinical course of HGSC. After estimating parameter values, we infer that most patients harbor chemoresistant HGSC cells at diagnosis and that, if the tumor burden is not too large and complete debulking can be achieved, PDS is superior to NACT due to better depletion of resistant cells. We further predict that earlier diagnosis of primary HGSC, followed by complete debulking, could improve survival, but its benefit in relapsed patients is likely to be limited. These predictions are supported by primary clinical data from multiple cohorts. Our results have clear implications for these key issues in HGSC management.
引用
收藏
页数:12
相关论文
共 77 条
[51]   Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin [J].
Lin, XJ ;
Howell, SB .
MOLECULAR PHARMACOLOGY, 1999, 56 (02) :390-395
[52]   Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study [J].
Liu, Ying L. ;
Zhou, Qin C. ;
Iasonos, Alexia ;
Chi, Dennis S. ;
Zivanovic, Oliver ;
Sonoda, Yukio ;
Gardner, Ginger ;
Broach, Vance ;
O'Cearbhaill, Roisin ;
Konner, Jason A. ;
Grisham, Rachel ;
Aghajanian, Carol A. ;
Abu-Rustum, Nadeem R. ;
Tew, William ;
Long Roche, Kara .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (12) :1915-1921
[53]   New developments in the treatment of ovarian cancer-future perspectives [J].
Lopez, J. ;
Banerjee, S. ;
Kaye, S. B. .
ANNALS OF ONCOLOGY, 2013, 24 :69-76
[54]   Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia [J].
Ma, Xiaotu ;
Edmonson, Michael ;
Yergeau, Donald ;
Muzny, Donna M. ;
Hampton, Oliver A. ;
Rusch, Michael ;
Song, Guangchun ;
Easton, John ;
Harvey, Richard C. ;
Wheeler, David A. ;
Ma, Jing ;
Doddapaneni, HarshaVardhan ;
Vadodaria, Bhavin ;
Wu, Gang ;
Nagahawatte, Panduka ;
Carroll, William L. ;
Chen, I-Ming ;
Gastier-Foster, Julie M. ;
Relling, Mary V. ;
Smith, Malcolm A. ;
Devidas, Meenakshi ;
Auvil, Jaime M. Guidry ;
Downing, James R. ;
Loh, Mignon L. ;
Willman, Cheryl L. ;
Gerhard, Daniela S. ;
Mullighan, Charles G. ;
Hunger, Stephen P. ;
Zhang, Jinghui .
NATURE COMMUNICATIONS, 2015, 6
[55]   Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials [J].
Mahner, S. ;
Eulenburg, C. ;
Staehle, A. ;
Wegscheider, K. ;
Reuss, A. ;
Pujade-Lauraine, E. ;
Harter, P. ;
Ray-Coquard, I. ;
Pfisterer, J. ;
du Bois, A. .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) :142-149
[56]   SHORT-TERM CIS-DIAMMINEDICHLOROPLATINUM(II) ACCUMULATION IN SENSITIVE AND RESISTANT HUMAN OVARIAN-CARCINOMA CELLS [J].
MANN, SC ;
ANDREWS, PA ;
HOWELL, SB .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 25 (04) :236-240
[57]  
Matulonis UA, 2018, CLIN ADV HEMATOL ONC, V16, P426
[58]   The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer [J].
May, Taymaa ;
Stewart, Jocelyn M. ;
Bernardini, Marcus Q. ;
Ferguson, Sarah E. ;
Laframboise, Stephane ;
Jiang, Haiyan ;
Rosen, Barry .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2018, 140 (02) :247-252
[59]   Mechanisms of Taxol resistance related to microtubules [J].
Orr, GA ;
Verdier-Pinard, P ;
McDaid, H ;
Horwitz, SB .
ONCOGENE, 2003, 22 (47) :7280-7295
[60]   Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582):: evidence for the role of transcription factor overexpression in determining resistant phenotype [J].
Pan, B ;
Yao, KS ;
Monia, BP ;
Dean, NM ;
McKay, RA ;
Hamilton, TC ;
O'Dwyer, PJ .
BIOCHEMICAL PHARMACOLOGY, 2002, 63 (09) :1699-1707